Skip to content

Exelixis EXEL Short- term Investments

Short- term Investments at other companies

Merck & Co. logo
Merck & Co.MRK
Gilead Sciences logo
Gilead SciencesGILD
Johnson & Johnson logo
Johnson & JohnsonJNJ
United Therapeutics logo
United TherapeuticsUTHR
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's short- term investments?
Exelixis (EXEL) reported short- term investments of $551.06M in Q1 2026.
How has Exelixis's short- term investments changed year-over-year?
Exelixis's short- term investments decreased by 35.0% year-over-year, from $847.56M to $551.06M.
What is the long-term trend for Exelixis's short- term investments?
Over 2 years (2023 to 2025), Exelixis's short- term investments has grown at a -11.3% compound annual growth rate (CAGR), from $732.31M to $576.6M.